Bosnia and Herzegovina vs Luxembourg: Statin use vs. average non-HDL cholesterol levels
Bosnia and Herzegovina
3.3
in 2018
Luxembourg
3.3
in 2018
Bosnia and Herzegovina rank
95th
Luxembourg rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Bosnia and Herzegovina
- Luxembourg
How they compare
Bosnia and Herzegovina currently reports 3.3 against 3.3 in Luxembourg, a difference of 0.
Across all 39 years both countries report, Luxembourg has been ahead every year.
Bosnia and Herzegovina ranks 95th and Luxembourg ranks 95th of 191 countries.
Luxembourg has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bosnia and Herzegovina | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.68 | 4.49 | 0.81 | Luxembourg |
| 1990s | 3.7 | 4.19 | 0.49 | Luxembourg |
| 2000s | 3.55 | 3.75 | 0.2 | Luxembourg |
| 2010s | 3.36 | 3.4 | 0.0444 | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Bosnia and Herzegovina or Luxembourg?
- Bosnia and Herzegovina, at 3.3 against 3.3 in Luxembourg as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Bosnia and Herzegovina and Luxembourg?
- 0, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Luxembourg?
- 39 years are reported by both, from 1980 to 2018.
- How do Bosnia and Herzegovina and Luxembourg rank globally for statin use vs. average non-hdl cholesterol levels?
- Bosnia and Herzegovina ranks 95th and Luxembourg ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.